Literature DB >> 35900615

Health-related quality of life in long-term Caribbean prostate cancer survivors: comparisons with prostate cancer-free men.

Maria D Jackson1, Evelyn Walker2, Marshall K Tulloch-Reid3.   

Abstract

PURPOSE: Prostate cancer (PCa) and its treatment can impact health-related quality of life (HRQoL). There are few studies of HRQoL in long-term PCa survivors of African ancestry from low- and middle-income countries. We examined the effect of PCa treatment on HRQoL of Jamaican PCa survivors compared with cancer-free controls and explored the effect of demographic and clinical factors on these outcomes.
METHODS: PCa survivors (n = 64) treated with and without ADT along with PCa-free controls (n = 88) from a case-control study of 10 years post enrolment. HRQoL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-C30). Effects of demographic and clinical variables on HRQoL on PCa and type of therapy were evaluated in multivariable linear regression models.
RESULTS: HRQoL of PCa survivors (overall and by treatment group) indicated a high quality of life, comparable to PCa-free men. However, ADT-treated survivors had lower physical functioning that was of small clinical relevance compared with those not on ADT. Symptom burden scores of PCa survivors and controls were similar excluding fatigue and dyspnoea which were highest in men on ADT and controls. In multivariable models, PCa was not an important determinant of overall HRQoL, functioning or symptom burdens. Underlying medical conditions and marital status were the main contributors to HRQoL in PCa survivors.
CONCLUSION: PCa cancer status was not an independent determinant of long-term HRQoL in Jamaican men. Interventions addressing social factors and comorbid illnesses could improve HRQOL in long-term PCa survivors.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  African ancestry; EORTC-QLQ-C30; Prostate cancer; Quality of life; Survivors

Year:  2022        PMID: 35900615     DOI: 10.1007/s11136-022-03202-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  42 in total

1.  Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Authors:  Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri
Journal:  JAMA       Date:  2011-12-07       Impact factor: 56.272

2.  Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.

Authors:  N A Spry; L Kristjanson; B Hooton; L Hayden; G Neerhut; H Gurney; T Corica; E Korbel; S Weinstein; K McCaul
Journal:  Eur J Cancer       Date:  2006-05-02       Impact factor: 9.162

3.  Categorization of Cancer Survivors: Why We Need It.

Authors:  Antonella Surbone; Paolo Tralongo
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

4.  Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls-results from a population-based study.

Authors:  Salome Adam; Daniela Doege; Lena Koch-Gallenkamp; Melissa S Y Thong; Heike Bertram; Andrea Eberle; Bernd Holleczek; Ron Pritzkuleit; Mechthild Waldeyer-Sauerland; Annika Waldmann; Sylke Ruth Zeissig; Lina Jansen; Sabine Rohrmann; Hermann Brenner; Volker Arndt
Journal:  Support Care Cancer       Date:  2019-11-18       Impact factor: 3.603

5.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  James L Mohler; Emmanuel S Antonarakis; Andrew J Armstrong; Anthony V D'Amico; Brian J Davis; Tanya Dorff; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E Ippolito; Christopher J Kane; Michael R Kuettel; Joshua M Lang; Jesse McKenney; George Netto; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; Thomas J Pugh; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J Small; Daniel E Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

6.  Health-related quality of life in long-term survivors with localised prostate cancer by therapy-Results from a population-based study.

Authors:  Salome Adam; Lena Koch-Gallenkamp; Heike Bertram; Andrea Eberle; Bernd Holleczek; Ron Pritzkuleit; Mechthild Waldeyer-Sauerland; Annika Waldmann; Sylke Ruth Zeissig; Sabine Rohrmann; Hermann Brenner; Volker Arndt
Journal:  Eur J Cancer Care (Engl)       Date:  2019-05-02       Impact factor: 2.520

7.  Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Authors:  Daniel A Galvão; Nigel A Spry; Dennis R Taaffe; Robert U Newton; John Stanley; Tom Shannon; Chris Rowling; Richard Prince
Journal:  BJU Int       Date:  2008-03-11       Impact factor: 5.588

Review 8.  Symptom burden and quality of life in survivorship: a review of the literature.

Authors:  Horng-Shiuann Wu; Janet K Harden
Journal:  Cancer Nurs       Date:  2015 Jan-Feb       Impact factor: 2.592

Review 9.  Current Cancer Epidemiology.

Authors:  Camilla Mattiuzzi; Giuseppe Lippi
Journal:  J Epidemiol Glob Health       Date:  2019-12

10.  Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.

Authors:  AnnMarie Groarke; Ruth Curtis; Jean Skelton; Jenny M Groarke
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.